112
Participants
Start Date
June 7, 2022
Primary Completion Date
January 15, 2024
Study Completion Date
January 15, 2024
ATX-101
ATX-101 (bupivacaine) implant, one-time administration into the surgical site
ATX-101
ATX-101 (bupivacaine) implant, one-time administration into the surgical site
bupivacaine hydrochloride without epinephrine
bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
Prince of Wales Private Hospital, Sydney
The Avenue Private Hospital, Windsor
John Flynn Private Hospital, Tugun
Royal Adelaide Hospital / PARC Clinical Research, Adelaide
St Andrew's Private Hospital, Adelaide
Durham Bone and Joint Specialists, Ajax
London Health Sciences Centre - University Hospital, London
Department of Trauma and Orthopaedic Surgery, Addenbrooke's Hospital, Cambridge
Southampton General Hospital, Southampton
Royal National Orthopaedic Hospital, Stanmore
Nottingham Elective Orthopaedic Service, Nottingham University Hospitals, Nottingham
Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry
Chapel Allerton Hospital C/O The Leeds Teaching Hospitals NHS Trust, Leeds
Lead Sponsor
Allay Therapeutics, Inc.
INDUSTRY